0001179110-20-004982.txt : 20200420
0001179110-20-004982.hdr.sgml : 20200420
20200420163639
ACCESSION NUMBER: 0001179110-20-004982
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200416
FILED AS OF DATE: 20200420
DATE AS OF CHANGE: 20200420
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Verstraete Stephany
CENTRAL INDEX KEY: 0001726419
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37477
FILM NUMBER: 20802915
MAIL ADDRESS:
STREET 1: C/O TELADOC, INC.
STREET 2: 2 MANHATTANVILLE ROAD, SUITE 203
CITY: PURCHASE
STATE: NY
ZIP: 10577
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Teladoc Health, Inc.
CENTRAL INDEX KEY: 0001477449
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
IRS NUMBER: 043705970
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 MANHATTANVILLE ROAD
STREET 2: SUITE 203
CITY: PURCHASE
STATE: NY
ZIP: 10577
BUSINESS PHONE: 2036352002
MAIL ADDRESS:
STREET 1: 2 MANHATTANVILLE ROAD
STREET 2: SUITE 203
CITY: PURCHASE
STATE: NY
ZIP: 10577
FORMER COMPANY:
FORMER CONFORMED NAME: Teladoc, Inc.
DATE OF NAME CHANGE: 20091123
4
1
edgar.xml
FORM 4 -
X0306
4
2020-04-16
0
0001477449
Teladoc Health, Inc.
TDOC
0001726419
Verstraete Stephany
C/O TELADOC HEALTH, INC.
2 MANHATTANVILLE ROAD, SUITE 203
PURCHASE
NY
10577
0
1
0
0
Chief Marketing Officer
Common Stock
2020-04-16
4
M
0
93597
17.99
A
106837
D
Common Stock
2020-04-16
4
S
0
93597
169.63
D
13240
D
Employee Stock Option (right to buy)
17.99
2020-04-16
4
M
0
93597
0.00
D
2026-01-04
Common Stock
93597
19403
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 2, 2020.
Represents the weighted average price of transactions ranging from $167.69 to $171.19. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
The option vested as to 25% of the shares on January 4, 2017. The remainder of the shares vested in 36 equal monthly installments thereafter.
/s/ Adam C. Vandervoort, attorney-in-fact
2020-04-20